Showing 1001-1010 of 1635 results for "".
- Senate Narrowly Passes COVID-19 Package That Includes ACA Subsidy Boost, Rural Hospital Moneyhttps://modernod.com/news/senate-narrowly-passes-covid-19-package-that-includes-aca-subsidy-boost-rural-hospital-money/2478944/The Senate narrowly approved a $1.9 trillion COVID-19 relief package that includes new funding for rural hospitals but not as much as hospital groups have asked for, according to a FierceHealthcare
- FDA Accepts Oyster Point’s Filing of NDA for OC-01 Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Diseasehttps://modernod.com/news/fda-accepts-oyster-points-filing-new-drug-application-for-oc-01-nasal-spray-for-the-treatment-of-signs-and-symptoms-of-dry-eye-disease/2478928/Oyster Point Pharma announced that the FDA has accepted its new drug application (NDA) for OC-01 (varenicline) nasal spray for the treatment of signs and symptoms of dry eye disease. The Prescription Drug User Fee Act (PDUFA) target action date for OC-01 (varenicline) nasal spray is October 17, 2
- FCI Ophthalmics Announces Availability of LacriJet for Monocanalicular Nasolacrimal Intubationhttps://modernod.com/news/fci-ophthalmics-announces-availability-of-lacrijet-for-monocanalicular-nasolacrimal-intubation/2478907/FCI Ophthalmics announced the launch of the LacriJet in the United States. It is the first, self-retaining monocanalicular nasolacrimal intubation preloaded on a single use injector, according to FCI Ophthalmics. LacriJet consists of a single use injector handpiece into which a silicone tu
- Re-Vana Therapeutics Names New Members to the Executive Teamhttps://modernod.com/news/re-vana-therapeutics-names-new-members-to-the-executive-team/2478897/Re-Vana Therapeutics announced the appointment of Michael Nash as Chief Commercial Officer and David Shima, PhD, as Vice President of Research and Development. The two executives will play critical leadership roles at Re-Vana as the company develops innovative sustained release therapies for a br
- Life Biosciences Announces Research in Nature Describing New Mechanisms for Reversing Age-Related Diseasehttps://modernod.com/news/life-biosciences-announces-research-in-nature-describing-new-mechanisms-for-reversing-age-related-disease/2478889/Life Biosciences has in-licensed intellectual property related to scientific findings recently described in two publications in the journal Nature. The publications, based on research conducted in animal models, report that therapies targeting the biology of aging have the potential to not
- Eyevance’s Natacyn Now Available for Next-Day Deliveryhttps://modernod.com/news/eyevances-natacyn-now-available-next-day/2478883/Eyevance Pharmaceuticals announced that its anti-fungal ophthalmic medication, Natacyn (natamycin ophthalmic suspension 5%), is now available for next-day delivery. Natacyn, which Eyevance acquired from Novartis in 2019, is indicated for the treatment of fungal blepharitis, conjunctivitis,
- Leo Lens Pharma Announces Corporate Name Change to MediPrint Ophthalmicshttps://modernod.com/news/leo-lens-pharma-announces-corporate-name-change-to-mediprint-ophthalmics/2478794/Leo Lens Pharma has announced a corporate name change to MediPrint Ophthalmics, effective immediately. The company also announced it has successfully closed an over-subscribed Seed round fundraising. The company’s rebranding to MediPrint Ophthalmics is based on input from stakeholders and
- James Reid Named CEO of Versant Healthhttps://modernod.com/news/james-reid-named-ceo-of-versant-health/2478762/MetLife announced that James Reid has been named CEO of Versant Health, a managed vision care company and wholly owned subsidiary of MetLife. The appointment is effective April 1. “James brings extensive and varied experience in the Group Benefits market to Versant Health,” Todd Katz, chai
- EnChroma Names Vision Industry Veteran Erik Ritchie as CEOhttps://modernod.com/news/enchroma-names-vision-industry-veteran-erik-ritchie-as-ceo/2478743/EnChroma, creators of EnChroma eyewear for color blindness, named Erik Ritchie as its CEO. Mr. Ritchie brings 25 years of experience in the optical industry and other fields. Most recently, he served as Chief Commercial Officer for Zenni Optical, the largest online provider of prescription eyewea
- Oyster Point Submits NDA to FDA for OC-01 Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Diseasehttps://modernod.com/news/oyster-point-pharma-submits-nda-to-fda-for-oc-01-nasal-spray-for-the-treatment-of-signs-and-symptoms-of-dry-eye-disease/2478677/Oyster Point Pharma announced it has submitted a 505(b)(2) new drug application (NDA) to the FDA for OC-01 (varenicline) nasal spray for the treatment of signs and symptoms of dry eye disease. The NDA submission is supported by safety and efficacy results from the phase 3 ONSET-2, phase 2b ONSET-